> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Comments Sought on Revisions to FDA Blueprint for Opioid Prescribers
- URL: https://www.fdaweb.com/comments-sought-on-revisions-to-fda-blueprint-for-opioid-prescribers/
- Published: 2017-05-10T12:00:00.000Z
- Updated: 2026-09-14T22:22:45.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5138658

*Federal Register* notice: FDA has announced the availability of [draft revisions](https://www.fda.gov/Drugs/NewsEvents/ucm553931.htm?ref=fdaweb.com) to the “FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics.” The Blueprint is part of the FDA-approved risk evaluation and mitigation strategy for extended release and long-acting opioid analgesic medications. FDA is also seeking comments on the draft revisions to the Blueprint. The agency is considering modifications to the existing Blueprint based on recommendations from a 5/2016 advisory committee meeting to include information on pain management, including the principles of acute and chronic pain management; non-pharmacologic treatments for pain; and pharmacologic treatments for pain (both non-opioid analgesic and opioid analgesic). To view the notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2017-05-10/pdf/2017-09442.pdf?ref=fdaweb.com).